Dear All, First up, we have an update to WHO’s review of the clinical antibacterial pipeline. The review by Butler et al. in AAC (and for transparency, know that I am a co-author) covers both traditional and non-traditional products. It found that as of 30 June 2021: There were 76 antibacterial agents in clinical development
Dear All, World Antimicrobial Awareness Week (WAAW) was such a mad scramble! So many events … just no way to attend everything. Some of the highlights in and around WAAW (not everything was precisely within the WAAW dates, thank goodness!) for me were: Andrew Jack and the team at FT (Financial Times) have released an
Dear All, WHO have released for consultation an updated draft of their EML (Essential Medicines List) Antibiotic handbook. For those not familiar with it, WHO’s EML (now in its 22nd edition!) provides a guide to a core set of medicines that every country should have. The antibiotic-focused version does this for antibiotics and then adds
Dear All, WHO continues on their streak of seeking support for their AMR-related work! Today we have a posting by the Tripartite Joint Secretariat on Antimicrobial Resistance (AMR) of a consultancy opening for an 11-month project that would support development of multisectoral guidance(s) on development and strengthening of the coordination mechanisms and governance structures for addressing AMR. Full details
Dear All, WHO are really busy these days! I was interested to see that WHO are hosting a pair of webinars entitled “The WHO Costing and Budgeting Tool for National Action Plans on AMR.” The webinars have the same basic content but different time zones. Here’s the agenda for one of them: Introduction Mr Anand Balachandran
Dear All, WHO are looking for multidisciplinary university groups or other scientific institutions to support the development of a One Health Priority Research Agenda on AMR! Per the RFP on the UN website (https://www.ungm.org/Public/Notice/146908), the terms of reference include scientific and methodological support for the following activities: Review of the grey literature and policy analysis of
Dear All, WHO are working steadily to maintain a comprehensive view of the clinical and preclinical pipelines. Such reports are invaluable in showing policymakers the need for continue Push/Pull in this area. Their 2020 clinical & pre-clinical antibacterial pipeline report was released in April of this year and discussed in detail in a 14 Apr 2021
Dear All (this newsletter experiments with an Executive Summary/Details format; let me know what you think), (Executive Summary) As a further support for implementation of recommendations from the UN Interagency Coordination Group on Antimicrobial Resistance (IACG AMR), the Tripartite Plus (WHO-FAO-OIE-UNEP) are seeking to create a Partnership Platform that will “engage institutions representing states, markets and
Dear All, First up today is a very interesting new workshop from FDA on 1-2 Sep entitled “Advancing the Development of Pediatric Therapeutics (ADEPT 7) Complex Innovative Trial Design.” In brief: “The Complex Innovative Trial Design Pilot Meeting Program (CID Program) facilitates and advances the use of complex and innovative trial designs that have the potential
Dear All, Deadline: 15 August 2021: The World Health Organization (WHO) is seeking experts to serve as members of the Advisory Group on the Bacterial Priority Pathogen List (AG BPPL). A “Call for experts” document provides information about the advisory group and the expert profiles being sought for the group. The document also provides information on